⚕ GalenOps CRO console
← SITE006 (GBR)

SITE006-0024

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE006 (GBR) (Dr. Rossi) · consented 2022-03-22
Adverse events
7
Serious AEs
3
Open data queries
0
Luna dropout signal
–

Adverse events

mild assessed 2026-08-18

Grade 1 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-03-31 (study day 3); relationship: not assessed

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-05-01 (study day 34); relationship: N

severe serious assessed 2026-08-18

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-05-07 (study day 40); relationship: N; serious criteria: hospitalization

moderate assessed 2026-08-18

Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-05-11 (study day 44); relationship: not assessed

severe serious assessed 2026-08-18

Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-22 (study day 55); relationship: Y; serious criteria: hospitalization

severe serious assessed 2026-08-18

Grade 4 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2022-05-27 (study day 60); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-06-15 (study day 79); relationship: not assessed

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.